

AWARD NUMBER: W81XWH-14-1-0410

TITLE: "Imaging Depression in Adults with ASD"

PRINCIPAL INVESTIGATOR: Kenneth Gadow, Ph.D.

CONTRACTING ORGANIZATION: The Research Foundation SUNY/Stony Brook
Stony Brook, NY 11794-3362

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE October 2017			12. REPORT TYPE ANNUAL		3. DATES COVERED 30Sep2016 - 29Sep2017	
4. TITLE AND SUBTITLE IMAGING DEPRESSION IN ADULTS WITH ASD					Sa. CONTRACT NUMBER	
					Sb. GRANT NUMBER W81XWH-14-1-0410	
					Sc. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) KENNETH GADOW, PH.D. E-MAIL: KENNETH.GADOW@STONYBROOKMEDICINE.EDU					Sd. PROJECT NUMBER	
					Se. TASK NUMBER	
					Sf. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) THE RESEARCH FOUNDATION SUNY/STONY BROOK OFFICE OF SPONSORED PROGRAMS W5510 MELVILLE LIBRARY STONY BROOK, NY 11794-3362					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND FORT DETRICK, MARYLAND 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED						
13. SUPPLEMENTARY NOTES						
14. ABSTRACT Aim A: To determine if the immunologic bias in autism spectrum disorder (ASD) confers greater risk for co-occurring depression than severity of ASD. If depression severity is associated with increased cytokine levels (reported in non-ASD adults), this would support the notion that depression is a valid clinical syndrome within the ASD clinical phenotype, but not necessarily the same disorder as in neurotypical populations. Aim B: To determine if depression symptoms are associated with clinical features similar to previous research about depression in neurotypical adults {e.g., brain activation in response to social stress and correlation with cytokine levels and depression severity}. If findings are consistent, this would support the notion that depression may be a "true" co-morbidity. Method: Participants will be men {N=50} 18-45 years old with IQ 80 and ASD diagnosis, no previous head trauma, no seizure or autoimmune disorder, and no current immunologic medication. Participants will be complete diagnostic and psychosocial assessments and a blood draw. A significant other will also complete emotion symptom measures. Individuals with low and high depression symptoms will be selected for participation the imaging phase. Functional scans will be acquired during a social acceptance/rejection task (Cyberball), followed by an exploratory hedonic reward task, Monetary Incentive Delay. The research is in progress with no results to report to date.						
15. SUBJECT TERMS AUTISM, BRAIN IMAGING, DEPRESSION, SOCIAL REJECTION						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC (code)	
a. REPORT	b. ABSTRACT	c. THIS PAGE				
U	U	U	UU	20		

Table of Contents

1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments	4
4. Impact	8
5. Changes/Problems	9
6. Products	10
7. Participants & Other Collaborating Organizations.....	11
8. Special Reporting Requirements	16
9. Appendices	17

1. INTRODUCTION:

Background: The main reason for conducting this study is to use brain imaging technology to better understand how the immune system and environmental stressors contribute to emotional symptoms in higher functioning adults with ASD. Hypotheses: (1) Severity of ASD and emotional symptoms in participants with ASD will each be associated with an elevated systemic inflammatory state indicated by increased peripheral levels of inflammatory cytokines (e.g., IL-6, TNF- α). (2) Participants undergoing fMRI will show (a) greater dorsal anterior cingulate cortex (dACC) activation following social rejection than social acceptance, and this will be (b) differentially greater in participants with elevated versus low emotion symptoms. (3) Higher levels of inflammatory cytokines will predict higher dACC activation following social rejection versus inclusion, and this will be moderated by emotional status (i.e., relation will be stronger among those in the high versus low emotion symptom group). Exploratory hypotheses will address parallel relations using an fMRI reward anticipation task. Method: Phase 1 participants will be men (N=50) between 18 and 45 years of age with a full scale IQ \geq 80 and diagnosis of ASD, and not be receiving psychotropic medication. ASD participants will be administered ASD and emotional assessment measures and complete a blood draw. A significant other will also complete emotion symptom measures. Individuals with low and high emotion symptoms will be selected for participation the Phase 2 imaging study. Functional scans will be acquired during a social acceptance/rejection task (Cyberball), which will be followed by an exploratory hedonic reward task, Monetary Incentive Delay.

2. KEYWORDS:

autism, brain imaging, depression, social rejection

3. ACCOMPLISHMENTS:

In this report, we detail the accomplishments met on the study to date, and propose a revised SOW for a second no-cost extension (Appendix A). All objectives enumerated in the revised SOW are consistent with those in the existing approved SOW.

YEAR 1: Revised SOW

What were the major goals of the project for Year 1?

Aim #1: Obtain Institution Review Board (IRB) approval for DOD application

1a. Task: Obtain IRB approval Responsible personnel: Dr. Gadow Milestone: IRB approval secured
SOW Timeline: Prior to award Week 0 (9/30/2014)
Actual Completion Date: 4/17/2014

1b. Task: Submit IRB DOD amendment to existing IRB approval
Responsible personnel: Dr. Gadow
Milestone: Complete and submit IRB amendment
SOW Timeline: Weeks 1-4 (10/7/2014 -10/28/2014)
Actual Completion Date: 7/28/2014

1c. Task: Obtain IRB amendment approval
Responsible personnel: Dr. Gadow
Milestone: Complete and submit revised IRB forms SOW Timeline: Weeks 4-6 (10/28/2014 - 11/11/2014) Actual Completion Date: 7/31/2014

Aim #2: Prepare for subject recruitment

2. Task: Prepare subject recruitment materials Responsible personnel: Dr. Gadow, Coordinator
Milestones: Solicitation lists, advertisements
SOW Timeline: Weeks 6-11 (11/11/2014- 12/16/2014) Actual Completion Date: 8/1/2014; 2/23/2015

Aim # 3: Recruitment, data collection, and data processing for Phase 1

3a. Task: Recruitment of first block of 28 Phase 1 participants Responsible personnel: Dr. Gadow, Coordinator Milestone: Initiate participant solicitation
SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 86% (Please see below for details and revised timeline)

3b. Task: Collect psychosocial data

Responsible personnel: Dr. Gadow, Dr. Lerner, Dr. Sprafkin, Coordinator Milestones: Administer diagnostic and psychosocial measures, collect blood samples SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015).

% of Milestone Complete: 0% (Please see below for details and revised timeline)

3c. Task: Record and enter diagnostic and psychosocial data Responsible personnel: Dr. Gadow, Dr. Lerner, Coordinator Milestones: Score assessment measures and enter data for analyses SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 0% (Please see below for details and revised timeline)

3d. Task: Collecting, storing, and processing Phase 1 immunologic data

Responsible personnel: Dr. Trujillo

Milestones: Collect and properly store blood samples

SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 0% (Please see below for details and revised timeline)

Aim # 4: Recruitment, data collection, and data processing for Phase 2

4a. Task: Recruitment of first block of 17 Phase 2 participants

Responsible personnel: Dr. Gadow, Dr. Lerner, Dr. DeLorenzo, Coordinator

Milestone: Initiate participant solicitation

SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 0% Please see below for details and revised timeline)

4b. Task: Conduct fMRI

Responsible personnel: Dr. Gadow, Dr. Lerner, Dr. DeLorenzo, Coordinator

Milestone: Conduct fMRIs

SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 0% (Please see below for details and revised timeline)

4c. Task: Storing and processing Phase 2 fMRI data

Responsible personnel: Dr. DeLorenzo

Milestones: Storing and initial processing fMRI data Weeks 12-52

SOW Timeline: Weeks 12-52 (12/23/2014- 9/30/2015)

% of Milestone Complete: 0% (Please see below for details and revised timeline)

What was accomplished under these goals for Year 1?

Aim #1: Obtain Institution Review Board (IRB) approval for DOD application

IRB approval at each step was secured well ahead of SOW timelines. Additionally, IRB renewal was required within this reporting period. Continuing Review materials were submitted to IRB on 2/23/2015, and approved on 5/5/2015; approval of Continuing Review was then submitted to USAMRMC ORP HRPO on 5/8/2015, and was acknowledged on 5/11/2015.

Aim #2: Prepare for subject recruitment

IRB-approved web postings and recruitment materials were disseminated upon amendment approval (i.e., 8/1/2014). A revised advertisement was submitted to IRB in Continuing Review (2/23/2015), which contains more information about the purpose and procedures of the study than original advertisement and updated telephone contact for the Coordinator. Upon IRB approval of the revised advertisement (5/5/2015), this new material was disseminated.

While these dates note specifically the preparation of subject materials, distribution efforts have been ongoing since 8/1/2014. As indicated in the IRB application, the primary recruitment method for this study is the distribution of approved recruitment materials via local clinical facilities, organizations, and individual providers who support this project, to target the ASD population, as opposed to disseminating recruitment materials to the public more broadly. Thus, our efforts on this task have focused on building and maintaining relationships with and providing recruitment

materials to local clinical contacts that have a combined reach of 200+ adult HFASD males. See Aim 3 below for preliminary yield.

Aim# 3: Recruitment, data collection, and data processing for Phase 1

3a. Milestones: Initiate participant solicitation

3b. Milestones: Administer diagnostic and psychosocial measures, collect blood samples

3c. Milestones: Score assessment measures and enter data for analyses

3d. Milestone: Collect, store, and process Phase 1 blood samples

Progress to Date: Recruitment efforts to date have yielded a pool of 24 prospective participants who have met preliminary screening criteria (e.g., existing diagnosis of HFASD, male) and have provided contact information, requesting to be contacted to enroll in the study. Additionally, PI Dr. Gadow, Co-I Dr. Lerner, and Coordinator have approval to hold informational tables advertising this study and other research participation opportunities of the PI Dr. Gadow and Co-I Dr. Lerner at two relevant local conferences: 1. Asperger Syndrome & High Functioning Autism Association's Fall Conference; 10/24/2015; attendees include educators, clinicians and administrators who work with ASD, as well as individuals with ASD and parents of individuals with ASD. 2. Meeting of the Minds Symposium on Autism Spectrum Disorders hosted by Stony Brook University Neurosciences Institute; 10/30/2015; open to all physicians, nurses, researchers, students and other healthcare professionals or caregivers with an interest in autism spectrum disorders, open to the public.

No subject was consented or enrolled in the full. As described in greater detail in Section 5 of this report and the supporting Appendices, data collection for the imaging phase of the study was delayed due to difficulties with the scanner. In order to (a) ensure that diagnostic and psychosocial data and blood samples from Phase 1 are collected temporally close enough to imaging data in Phase 2 to be confidently incorporated in the planned statistical analyses, and (b) not unduly risk attrition between Phase 1 and 2, we chose to hold off on Phase 1 data collection until scanner issues were resolved and Phase 2 data collection is imminent.

Aim # 4: Recruitment, data collection, and data processing for Phase 2

As described in greater detail in Section 5 of this report and the supporting Appendices, data collection for the imaging phase of the study were delayed due to difficulties with the scanner. Please see Appendix A: Revised SOW for the timeline to complete this Aim.

YEAR 2: Revised SOW

What were the major goals of the project for Year 2?

Aim # 3: Recruitment, data collection, and data processing for Phase 1

3a. Task: Recruitment of first block of 10 Phase 1 participants

Responsible personnel: Dr. Gadow, Coordinator

Milestone: Continue participant solicitation

Timeline: Weeks 1-34 (10/1/2015 – 6/1/2016)

3b. Task: Collect psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Administer diagnostic and psychosocial measures, collect blood samples

Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

3c. Task: Record and enter diagnostic and psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Score assessment measures and enter data for analyses

Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

3d. Task: Collecting and storing Phase 1 immunologic data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Collect and properly store blood samples

Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

Aim # 4: Recruitment, data collection, and data processing for Phase 2

4a. Task: Recruitment of first block of 3 Phase 2 participants
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator
Milestone: Initiate participant solicitation
Timeline: Weeks 39-52 (7/1/2015 – 9/30/2016)

4b. Task: Conduct fMRI
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator
Milestone: Conduct fMRIs
Timeline: Weeks 39-52 (7/1/2015 – 9/30/2016)

4c. Task: Storing and processing Phase 2 fMRI data
Responsible personnel: Dr. DeLorenzo
Milestones and timeline: Storing and initial processing fMRI data Weeks 39-52 (7/1/2015 – 9/30/2016)

What was accomplished under these goals for Year 2?

Aim# 3: Recruitment, data collection, and data processing for Phase 1

3a. Milestones: Initiate participant solicitation

3b. Milestones: Administer diagnostic and psychosocial measures, collect blood samples

3c. Milestones: Score assessment measures and enter data for analyses

3d. Milestone: Collect, store, and process Phase 1 blood samples

Progress to Date: Recruitment efforts to date have yielded a pool of 70 prospective participants to date who have met preliminary screening criteria (e.g., existing diagnosis of HFASD) and have provided contact information, requesting to be contacted to enroll in the study. Additionally, PI Dr. Gadow, Co-I Dr. Lerner, and Coordinator have approval to hold informational tables advertising this study and other research participation opportunities of the PI Dr. Gadow and Co-I Dr. Lerner at two relevant local conferences: 1. Asperger Syndrome & High Functioning Autism Association's Fall Conference; 10/15/2016; attendees include educators, clinicians and administrators who work with ASD, as well as individuals with ASD and parents of individuals with ASD.

Five subjects have consented to and enrolled in Phase 1 of the study to date. As described in greater detail in Section 5 of this report and the supporting Appendices, data collection for the imaging phase of the study was previously delayed due to difficulties with the scanner. In order to (a) ensure that diagnostic and psychosocial data and blood samples from Phase 1 are collected temporally close enough to imaging data in Phase 2 to be confidently incorporated in the planned statistical analyses, and (b) not unduly risk attrition between Phase 1 and 2, we chose to hold off on Phase 1 data collection until scanner issues were resolved and Phase 2 data collection was imminent.

Aim # 4: Recruitment, data collection, and data processing for Phase 2

Two date one participant successfully completed the Phase 2 scan, and a second participant completed the scan 10/12/16. Please see Appendix A: Revised SOW for the timeline to complete this Aim.

YEAR 3: Revised SOW

What were the major goals of the project for Year 3?

Aim # 3: Recruitment, data collection, and data processing for Phase 1

3a. Task: Recruitment of first block of Phase 1 participants

Responsible personnel: Dr. Gadow, Coordinator

Milestone: Continue participant solicitation

Timeline: Weeks 1-34 (10/1/2016 – 6/1/2017)

3b. Task: Collect psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Administer diagnostic and psychosocial measures, collect blood samples

Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

3c. Task: Record and enter diagnostic and psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Score assessment measures and enter data for analyses

Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

3d. Task: Collecting and storing Phase 1 immunologic data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Collect and properly store blood samples

Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

Aim # 4: Recruitment, data collection, and data processing for Phase 2

4a. Task: Recruitment of first block of 3 Phase 2 participants

Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator

Milestone: Initiate participant solicitation

Timeline: Weeks 39-52 (7/1/2016 – 9/30/2017)

4b. Task: Conduct fMRI

Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator

Milestone: Conduct fMRIs

Timeline: Weeks 39-52 (7/1/2016 – 9/30/2017)

4c. Task: Storing and processing Phase 2 fMRI data

Responsible personnel: Dr. DeLorenzo

Milestones and timeline: Storing and initial processing fMRI data Weeks 39-52 (7/1/2016–9/30/2017)

What was accomplished under these goals for Year 3?

Aim# 3: Recruitment, data collection, and data processing for Phase 1

3a. Milestones: Initiate participant solicitation

3b. Milestones: Administer diagnostic and psychosocial measures, collect blood samples

3c. Milestones: Score assessment measures and enter data for analyses

3d. Milestone: Collect, store, and process Phase 1 blood samples

Data collection for the imaging phase of the study in Year 3 was delayed in January when our IRB met but could not review our renewal application as they did not have a quorum. The renewal application was submitted on schedule. The following review slot was delayed as a result of a snowstorm. Both issues have been resolved and will not be a problem going forward. However, it was of course necessary to delay recruitment until the IRB approved the renewal.

Another delay has been the reliance on part-time nurses to be in the scanner during the scan. This issue is being resolved by the Hospital's hiring a dedicated fulltime nurse for the scanner. This has been resolved as the post is now filled. We continued to conduct new Phase One evaluations while we were waiting for the new hire.

I have been able to recruit three students, one of whom is a PhD candidate in neuropsychology, and all have been well-trained over the past ten months. My PhD candidate will be with me for the next two and half years and is a highly capable Project Coordinator.

We have made good progress in conducting preliminary analyses of our Phase One data, and our preliminary efforts to set up the pipeline for our fMRI data analyses are well underway.

We are actively collaborating with colleagues in CUBIT who are also conducting studies on the same scanner, and moving forward we will be able to conduct analyses comparing scan data from their subjects with our sample. To date, Co-I Dr. Lorenzo has evaluated 20 male adults with major depressive episode on the same scanner and also collected data on important measures relevant to this study. In addition to the obvious economies of scale, this will be a huge asset in our bid for follow-up, large-scale grant funding which is the desired outcome for this DoD Pilot Award. In sum, the project is doing well with a high probability of success as all the technical issues associated with a new scanner have clearly been resolved as the data generated are exactly what we have expected in terms of quality and validity. Furthermore, the

resolution of the staff issue is already nearing completion.

Twenty three participants have consented to and enrolled in Phase 1 of the study to date. An additional three participants are scheduled for Phase 1 evaluations in October 2017 (10-17-17, 10-19-17, 10-20-17).

Aim # 4: Recruitment, data collection, and data processing for Phase 2

Two date nine participants successfully completed the Phase 2 scan, and a tenth participant completed the scan 10/5/17. An additional four participants are currently scheduled for scans in November 2017 and they are scheduled for 11-3-17, 11-14-17, 11-20-17, 11-22-17. Please see Appendix A: Revised SOW for the timeline to complete this Aim.

What opportunities for training and professional development has the project provided?

- PI Dr. Gadow and Co-I Dr. Lerner have each mentored Coordinator Rebecca Weber one-on-one in data management and analytic techniques.
- Coordinator Rebecca Weber and Co-I Dr. Lerner's Clinical Psychology PhD students have participated in weekly training for the Structured Clinical Interview for DSM IV to be administered in Phase 1, for which weekly clinical supervision is ongoing (since 9/2014).
- Co-I Dr. Lerner's 2nd year Clinical Psychology PhD students have participated in ADOS-2 Introductory Clinical Training and ADOS-2 Advanced/Research Training by New York Presbyterian Center for the Developing Brain (CADS), Weill Cornell Medical College, & Columbia University Medical Center (7/2014) and successfully undergone review to be certified (12/2014, 7/2015) as research-reliable examiners for this gold-standard ASD diagnostic assessment (Autism Diagnostic Observation Schedule, 2nd edition), to be administered in Phase 1.
- Likewise, Co-I Dr. Lerner's 1st year Clinical Psychology PhD has participated in ADOS-2 Introductory Clinical Training by New York University Child Study Center (8/2015) and ADOS-2 Advanced/Research Training by Weill Cornell Medical College & CADB (10/2015), and is currently completing steps toward reliability review.
- Co-I Dr. Lerner has trained Coordinator Rebecca Weber and his Clinical Psychology PhD students in administration of the Kaufman Brief Intelligence Test, 2nd edition, to be administered in Phase 1 (7/2014).
- Coordinator Rebecca Weber has completed training and certification in Phlebotomy for Research (Adults) at Stony Brook University Hospital, which consisted of 3 hours of classroom instruction (9/2014) and 20 hours of practicum with adult inpatients and outpatients under direct supervision of Stony Brook University Hospital Phlebotomy staff (11/2014). Coordinator will be responsible for Phase 1 blood draws.

How were the results disseminated to communities of interest?

Nothing to Report.

What do you plan to do during the next reporting period to accomplish the goals?

As detailed Appendix A: Revised SOW for Year 4, the goals for the next reporting period revolve around data collection for the remaining Phase 1 and 2 participants. The reasons for the revised timeline we enumerated previously in this report. We are confident in the timelines for milestones outlined in the Revised SOW, as a solution to the cause of the delays have been reached.

PI Dr. Gadow, his Coordinator and students will continue to seek out ASD community events/conferences for additional future large-scale recruitment opportunities to supplement interest generated by local clinical contacts as needed to maintain target enrollment rates.

PI Dr. Gadow will oversee collection of diagnostic and psychosocial data by Coordinator and Clinical Psychology PhD students and will provide clinical guidance throughout the study on a subject-by-subject basis as needed to ensure high quality of diagnostic and psychosocial data. PI Dr. Gadow and Co-I Dr. DeLorenzo will oversee Phase 2 data collection, for which the Coordinator will be present for all subjects. All investigators have extensive experience in collecting, storing, and processing the type of data for which they are responsible on this project.

4. IMPACT:

What Was the impact on the development of the principal discipline(s) of the project?

Nothing to Report.

What Was the impact on other disciplines?

Nothing to Report.

What was the impact on technology transfer?

Nothing to Report.

What was the impact on society beyond science and technology?

Nothing to Report.

5. CHANGES/PROBLEMS:

Changes in approach and reasons for change:

Nothing to Report.

Actual or anticipated problems or delays and actions or plans to resolve them:

The major problem encountered in Year 3 was staffing the scanner. This problem has been resolved. This has had no impact on the expenditures of the grant nor the direction of the project; the only impact identified pertains to time, which is addressed in Appendix A.

Changes that had a significant impact on expenditures:

Nothing to Report.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Nothing to Report.

6. PRODUCTS:

- Publications, conference papers, and presentations. Nothing to report.
- Journal publications. Nothing to Report.
- Books or other non-periodical, one-time publications. Nothing to Report.
- Other publications, conference papers, and presentations. Nothing to Report.
- Website(s) or other Internet site(s) Nothing to Report.
- Technologies or techniques Nothing to Report.
- Inventions, patent applications, and/or licenses Nothing to Report.
- Other Products Nothing to Report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

1. Name: Kenneth D. Gadow, PhD
Contribution to Project: No change.
2. Name: Ramin Parsey, MD, PhD
Contribution to Project: No change.
3. Name: Christine DeLorenzo, PhD
Contribution to Project: No change.
4. Name: Matthew Lerner, PhD
Contribution to Project: No change.
5. Name: Patricia Whitaker-Azmitia, PhD
Contribution to Project: No change.
6. Name: Jie Yang, PhD
Contribution to Project: No change.
7. Name: Project
Role: Glenda Trujillo, PhD
Person months worked: Co-Investigator
Contribution to Project: 0.02
Dr. Trujillo made recommendations for the assays to be used for analysis of immunologic markers in Phase 1 blood samples, for the collection of these samples, and for the Coordinator's phlebotomy training to be tailored to the needs of this protocol.
Funding Support: Dr. Trujillo's salary support at 2% effort has ended due to her resignation, effective 11/14/2014.
8. Name: Project
Role: Joyce Sprafkin, PhD
Person months worked: Co-Investigator
Contribution to Project: None
Clinician. Dr. Sprafkin retired, effective April 2015.
9. Name: Project Role: Rebecca Weber,
Contribution to Project: BA Coordinator
Position termed 9-30-16
10. Name: Project Role: Heather Garman, MS
Contribution to Project: Coordinator
Position started 10-01-16

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Kenneth D. Gadow, PhD
No change.

Ramin Parsey, MD, PhD

ACTIVE SUPPORT:

Advancing Personalized Antidepressant Treatment Using PET/MRI; NIMH; PI: DeLorenzo. R01 MH104512; 5/1/15-4/30/19; Goals/Aims: To predict response to antidepressant treatment and develop non-invasive techniques for PET imaging; Role: Co-I. CM:24. Agency Contracting/Grants Officer: Dr. Judith M. Rumsey. *This project has no financial or substantive overlap with AR130397.* Active support not yet pending at last submission.

Biosignatures of Treatment Remission in Major Depression; NIMH; PI's: Weissman, Parsey, McGrath. 5U01 MH092250-04; 07/01/10-06/30/16; Goals/Aims: This multi-site study will compare a serotonin selective reuptake inhibitor and placebo and assess a comprehensive array of clinical and biological moderators and mediators of outcome. Using innovative statistical approaches, the identified moderators and mediators will then be used to develop a differential depression treatment response index as a first step to developing personalized medication treatment of major depression disorder. Role: Co-PI. CM:6. *This project has no financial or substantive overlap with AR130397.* No change.

Lithium's Molecular Mechanism of Action and the Pathology of Bipolar Disorders; NIMH. 1 R01 MH090276-01A1; 06/01/12-05/31/16; Goals/Aims: This project will utilize MRI and PET imaging techniques to investigate the molecular mechanisms of lithium in a bipolar patient population compared to healthy controls. This work will further develop our understanding of the pathology of bipolar, and will contribute to our understanding of personal diagnosis and treatment. Role: PI. CM:4. *This project has no financial or substantive overlap with AR130397.* No change.

Understanding the Molecular Mechanism of Action of Electroconvulsive Therapy in vivo Using Positron Emission Tomography; Brain & Behavior Research Foundation. 08/01/12- 07/31/16; Goals/Aims: This study will use positron emission tomography to provide data essential for the understanding of the role of the 5-HT_{1A} receptor in major depressive disorder and specifically electroconvulsive therapy's antidepressant mechanism of action. By understanding the neurochemical mechanisms involved not only in the pathophysiology of major depressive disorder but also the therapeutic action of ECT, significantly improved therapies can be developed. Role: PI. CM:24. *This project has no financial or substantive overlap with AR130397.* No change.

Characterizing Placebo Response; NIH; PI: Petkova. 1 R01 MH99003-01; 12/01/13- 11/30/15; Goals/Aims: Clinical expertise will be provided to guide methodology development, interpret results, and real-data validation of project's models. Role: Co-I. CM:54. *This project has no financial or substantive overlap with AR130397.* No change.

PREVIOUS SUPPORT:

Understanding the Mechanism of Action of Lithium and the Pathophysiology of Bipolar Disorder with Molecular Imaging of the Serotonin System; The DANA Foundation. 08/01/13- 07/30/13; Goals/Aims: Examination of the effects of lithium of the serotonin transporter and 1A receptor; Role: PI. CM:0. *This project has no financial or substantive overlap with AR130397.* Now completed support, active at last submission.

Christine Delorenzo, PhD

ACTIVE SUPPORT:

Advancing Personalized Antidepressant Treatment Using PET/MRI; NIMH. R01MH104512; 5/1/15- 4/30/19; Goals/Aims: To predict response to antidepressant treatment and develop non-invasive techniques for PET imaging; Role: PI. 25% effort. Agency Contracting/Grants Officer: Dr. Judith M. Rumsey. *This project has no financial or substantive overlap with AR130397.*
Active support not yet pending at last submission.

Uncovering an Image-Based Biomarker of Depression; Stony Brook University. Fusion Seed Grant; 8/2015 – 6/2017; Goals/Aims: The goal of this grant is to develop an image-based biomarker of depression; Role: PI(no salary support). Agency Contracting/Grants Officer: Dr. Una M Obeid. *This project has no financial or substantive overlap with AR130397.*
Active support not yet pending at last submission.

Prediction of Antidepressant Treatment Response Using Magnetic Resonance Imaging (MRI); Dana Foundation. David Mahoney Neuroimaging Grant; 10/2015- 9/2018; Goals/Aims: To develop a high resolution diffusion imaging sequence to assess the health of white matter tracts prior to antidepressant treatment for the purposes of prediction; Role: PI(no salary support). Agency Contracting/Grants Officer: Kevin Aguirre. *This project has no financial or substantive overlap with AR130397.*
Active support not yet pending at last submission.

Personality Development and Vulnerability to First-Episode Depression; NIMH; Supplement to R01MH093479; 2014- 2017; Goals/Aims: In this project, we examine personality development, alongside other vulnerabilities, as a risk factor for first onset of depression. These vulnerabilities are related to structural and functional neuroimaging; Role: Co-I. 20% effort year 2. Agency Contracting/Grants Officer: Dr. Mercedes Rubio. *This project has no financial or substantive overlap with AR130397.*
No change.

Cognitive Impairment in MS Linked to Structural and Functional Connectivity; Department of Defense; PI Dr. Lauren Krupp. MS130103; 2014- 2016; Goals/Aims: To use brain imaging to understand how the MS disease process causes cognitive impairment; Role: Co-I. 16% effort. Agency Contracting/Grants Officer: Peggi Lesnow. *This study involves many of the same types of imaging as the current proposal. However it is significantly different in that it is focused only on Multiple Sclerosis.*
No change.

PREVIOUS SUPPORT:

Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET Ligand; NIMH. 5K01MH091354-01; 5/1/11 – 4/30/15; Goals/Aims: To characterize the PET ligand [^{11}C]ABP688 for use in studies of depression and other mood disorders; Role: PI. 75% effort. Agency Contracting/Grants Officer: Dr. Christine Wise Clarkson. *This project has no financial or substantive overlap with AR130397.*
Now completed support, active at last submission.

Uncovering Biomarkers of Major Depressive Disorder Using Multimodal Imaging; Irving Institute for Clinical and Translational Research Grant, Columbia University; 03/01/12 – 2/28/14; Goals/Aims: To combine several imaging modalities, using advanced machine learning and

statistical classification techniques that have been successful in integrating large amounts of information in other fields; Role: PI. Agency Contracting/Grants Officer: Michelle A. McClave. *This study involved many of the same types of imaging as the current proposal. However it was significantly different in that (1) It is focused only on depression (and not autism), (2) The imaging did not involve the highest resolution options or the simultaneous PETIMRI scanner, and (3) it was focused on methodology.*

Now completed support, active at last submission.

Fronto-striatal circuitry in Parkinson's Disease; Hartman Foundation; PI Hoi-Chung Leung; 2013 – 2014; Goals/Aims: To develop neuroimaging experiments to examine functional and anatomical connectivity changes in patients in early stages of Parkinson's Disease; Role: Co-I.

20% effort. Agency Contracting/Grants Officer: Catherine Costanzo. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

Recruitment of Women in Biomedical Engineering (BME) through Mentored Internships in Neuroimaging; Presidential Mini-Grants for Departmental Diversity Initiative; 9/1/2013-06/30/2014; Goals/Aims: This funding is used to establish a pilot program providing medical imaging internships to undergraduate women throughout the academic year. Through guided research in state-of-the-art biomedical engineering (neuroimaging) techniques within a supportive and encouraging community, this highly technical and multidisciplinary field will be both accessible and enjoyable to participants. This will encourage women to major in engineering disciplines; Role: PI. Agency Contracting/Grants Officer: Barbara Doran-Lubitz. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

Matthew Lerner, PhD

ACTIVE SUPPORT:

A Web-Based Tool to Assess Social Cognition in ASD; Simons Foundation. Explorer Award; 11/2015 -11/2016; Aims: 1) To evaluate the internal consistency of SELweb module scores. 2) To assess criterion validity of SELweb in comparison with existing social cognitive measures. 3) To evaluate SELweb performance in comparison to established normative data from general education youth; Role: PI. CM:1.0. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Effects of Active Emotion Identification; Alan Aida Fund for Communication. 05/2015 – 05/2016; Aims: 1) To assess whether AEI relates to specific psychophysiological mechanisms of social perception and cognition. 2) To determine if engagement in AEI relates to sustained changes social perception, cognition, and behavior across levels of analysis. 3) To ascertain whether effects on social perception, cognition, and behavior are evident in a "high need" population of young adults with ASD; Role: PI. CM:1.0. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Theater in School to Promote Youth with ASD - Pilot Study; Arts Connection. 10/2015 – 06/2017; Aims: 1) To identify and isolate elements of a school-based theater arts program (STAARS) thought to be related to social and academic outcomes in the special population of children with ASD by consulting stakeholders and observing students. 2) To determine whether the elements identified relate to changes in children's social, language, planning and attention

skills, and creativity; Role: Co-PI. CM:1.5. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Improving Effectiveness of Behavior Management Strategies at Maryhaven; Maryhaven Center of Hope. 8/15/15- 12/15/16; Goal/Aims: To identify factors associated with increased IISCIPI-R gradient and injuries employing a comprehensive dataset obtained at Maryhaven during the 2014 calendar year; Role: PI. CM:28. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Consortium on Autism & Sign Language; American Academy of Arts & Sciences. Exploratory Fund; 03/2015-03/2016; Goals/Aims: We will hold a two-day symposium of Academy Fellows as well as nationally known researchers in two areas: sign language linguistics and the study of social communication among individuals with autism spectrum disorders (ASD). The symposium will be held at the Norton Woods Conference Center at the House of the Academy in Cambridge in mid-December 2015; Role: Co-PI. CM:1.0. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Electrophysiological Effects of Social Performance-based Intervention for Autism Spectrum Disorder: A Randomized Controlled Trial; Stony Brook University, Department of Psychiatry. Pilot Grants Program; 07/2015-07/2016; Aims: 1) Does SDARI affect neural mechanisms of social perception and cognition? 2) Do baseline characteristics predict response to SDARI?; Role: PI. CM:1.0. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Cognitive Consequences of Emotion; National Science Foundation; PI: Gerald Clore, PhD, University of Virginia. 1252079; 2013-2016; Aims: 1) To understand effects of emotional states on perception, memory, and creativity. 2) To assess the affect-as-information hypothesis on judgments in individuals with and without a predisposition towards a local processing focus; Role: Co-I. CM:25. *This project has no financial or substantive overlap with AR130397.*

Active support not yet pending at last submission.

Consortium on Autism & Sign Language; Nancy Lurie Marks Family Foundation. Sponsored Symposium Grant; 2014-2015; Goals/Aims: Same as American Academy of Arts & Sciences, above; Role: PI. CM:6. *This project has no financial or substantive overlap with AR130397.* Active support not yet pending at last submission.

PREVIOUS SUPPORT:

No change.

Patricia Whitaker-Azmitia, PhD
No change.

Jie Yang, PhD
Jie Yang, PhD

ACTIVE SUPPORT:

ME/CFS: Activity Patterns and Autonomic Dysfunction. 1R01NR016227-01 Friedberg (PI) 04/01/2016-03/31/2020. Goal:1) To assess the relation between non-improvement and prospectively assessed activity patterns and life events; 2) To assess the relation between improvement and prospectively assessed activity patterns and life events.; 3) To assess the relation between activity patterns and symptoms. *This project has no financial or substantive overlap with AR130397.*

No change

Advancing Virtual Colonoscopy for Early Cancer Screening. 1R01CA206171-01A1 Liang (PI) 06/03/2016-05/31/2021. Goal: 1) To develop and evaluate adaptive image reconstruction and image processing algorithms to retain image textures for polyp detection and characterization with as low as achievable CT radiation; 2) To explore and evaluate texture features as imaging biomarkers to detect polyps and characterize polyp Subtypes. *This project has no financial or substantive overlap with AR130397.*

No change

P13K Signaling and Channelopathies in the Heart. 1R01DK108989 Lin (PI) 07/01/2016-06/30/2020. Goal: to examine how PI3K/Akt regulates the function of Nav1.5 and HCN2 channels and investigates the effects of insulin resistance on I_{NaP} and I_h . *This project has no financial or substantive overlap with AR130397.*

No change

Sphingolipids in Cancer Therapy and Biology. 2P01CA09713211A1 Hannun (PI) 09/02/2014-

08/30/2019. Goal: To investigate the role of sphingolipids in tumor initiation and differentiation, growth and death of tumor cells, tumor cell invasiveness and metastasis and tumor senescence. Role: Lead Biostatistician. 20% effort. *This project has no financial or substantive overlap with AR130397.*

No change.

PREVIOUS SUPPORT:

Targeted Approach for Prevention and Therapy of Colorectal Cancer. 1R01CA17211301A1

Yang (PI) 07/01/2013-06/30/2017. Goal: To evaluate a novel compound which potently and selectively inhibits KLF5 as a therapeutic candidate for colorectal cancer. Role: Co-I. 1.5% effort. *This project has no financial or substantive overlap with AR130397.*

No change.

Plasticity-based, adaptive, computerized cognitive remediation treatment (PACR) for adults with

Multiple Sclerosis (MS). RG 4808A8/1 Krupp (PI) 04/03/2013-03/31/2016. Goals: 1) To evaluate the effect of plasticity-based, adaptive, computerized cognitive remediation ("PACR") on generalized cognitive and functional performance, 2) To identify specific predictors of response to guide future use; Role: Co-I. 4.5% effort for year 1-2; 9% effort for year 3. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

Cognitive Impairment in MS Linked to Structural and Functional Connectivity Effect.

W81XWH1410248 Krupp (PI) 9/29/2014-9/28/2016. Goals: 1) To measure cognitive Intra Individual Variability (IIV) in multiple Sclerosis MS and healthy control participants to serve as an index of cognitive impairment and measure structural, functional and metabolic imaging markers to serve as indices of MS disease pathology, 2) To link these measures to identify the biological basis of cognitive impairment in MS. Role: Co-I. 10% effort. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

A Pilot Study of Regional Cerebral Oxygen Saturation (rS02) Monitoring in Predicting Neurological and Survival Outcomes. 13CRP17440000 Parnia (PI) 07/01/2013-06/30/2015. Goals: To measure the level of rS02 achieved during CPR and in the first 24 hours of the post resuscitation period in cardiac arrest patients to investigate the level of rS02 and optimal read out signal that is associated with survival, neurological and functional outcomes at discharge, and 30 days following cardiac arrest. Role: Co-I. 1°/o effort. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

Screening Lung Cancer by Ultra Low-Dose Computed Tomography. 5R01CA143111 Liang (PI)

07/01/2010-04/30/2015. Goal: To reduce the X-ray exposure risk by lowering the mAs value as low as achievable, while retaining the image quality suitable to the clinical task. Role: Co-I.

3.2o/o effort. *This project has no financial or substantive overlap with AR130397.*

Now completed support, active at last submission.

Now completed support, active at last submission.

What other organizations were involved as partners? Nothing to Report.

8. SPECIAL REPORTING REQUIREMENTS: None.

9. APPENDICES:

Revised SOW

YEAR 1

Aim #1: Obtain Institution Review Board (IRB) approval for DOD application

1a.Task: Obtain IRB approval

Responsible personnel: Dr. Gadow

Milestone: IRB approval secured

Timeline: Prior to award Week 0 (9/30/2014)

1b.Task: Submit IRB DOD amendment to existing IRB approval

Responsible personnel: Dr. Gadow

Milestone: Complete and submit IRB amendment

Timeline: Weeks 1-4 (10/7/2014 – 10/28/2014)

1c.Task: Obtain IRB amendment approval

Responsible personnel: Dr. Gadow

Milestone: Complete and submit revised IRB forms

Timeline: Weeks 4-6 (10/28/2014 – 11/11/2014)

Aim #2: Prepare for subject recruitment

2. Task: Prepare subject recruitment materials

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Solicitation lists, advertisements

Timeline: Weeks 6-11 (11/11/2014 – 12/16/2014)

Aim # 3: Prepare for Phase 1 and Phase 2 data collection

3a. Task: Prepare for data collection

Responsible personnel: Dr. Gadow, Coordinator

Milestone: Pilot test fMRI task and conduct Phase 2 wet runs

Timeline: Weeks 12-52 (12/23/2014 – 9/30/2015)

YEAR 2

Aim # 3: Recruitment, data collection, and data processing for Phase 1

3a. Task: Recruitment of first block of 10 Phase 1 participants

Responsible personnel: Dr. Gadow, Coordinator

Milestone: Continue participant solicitation

Timeline: Weeks 1-34 (10/1/2015 – 6/1/2016)

3b. Task: Collect psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Administer diagnostic and psychosocial measures, collect blood samples

Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

3c. Task: Record and enter diagnostic and psychosocial data

Responsible personnel: Dr. Gadow, Coordinator

Milestones: Score assessment measures and enter data for analyses

Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

3d. Task: Collecting and storing Phase 1 immunologic data
Responsible personnel: Dr. Gadow, Coordinator
Milestones: Collect and properly store blood samples
Timeline: Weeks 34-52 (6/1/2016 – 9/30/2016)

Aim # 4: Recruitment, data collection, and data processing for Phase 2

4a. Task: Recruitment of first block of 3 Phase 2 participants
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator
Milestone: Initiate participant solicitation
Timeline: Weeks 39-52 (7/1/2015 – 9/30/2016)

4b. Task: Conduct fMRI
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator
Milestone: Conduct fMRIs
Timeline: Weeks 39-52 (7/1/2015 – 9/30/2016)

4c. Task: Storing and processing Phase 2 fMRI data
Responsible personnel: Dr. DeLorenzo
Milestones and timeline: Storing and initial processing fMRI data Weeks 39-52 (7/1/2015-9/30/2016)

YEAR 3

Aim # 3: Recruitment, data collection, and data processing for Phase 1

3a. Task: Recruitment of first block of Phase 1 participants
Responsible personnel: Dr. Gadow, Coordinator
Milestones: Continue participant solicitation
Timeline: Weeks 1-34 (10/1/2016 – 6/1/2017)

3b. Task: Collect psychosocial data
Responsible personnel: Dr. Gadow, Coordinator
Milestones: Administer diagnostic and psychosocial measures, collect blood samples
Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

3c. Task: Record and enter diagnostic and psychosocial data
Responsible personnel: Dr. Gadow, Coordinator
Milestones: Score assessment measures and enter data for analyses
Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

3d. Task: Collecting and storing Phase 1 immunologic data
Responsible personnel: Dr. Gadow, Coordinator
Milestones: Collect and properly store blood samples
Timeline: Weeks 34-52 (6/1/2017 – 9/30/2017)

Aim # 4: Recruitment, data collection, and data processing for Phase 2

4a. Task: Recruitment of first block of 3 Phase 2 participants
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator
Milestone: Initiate participant solicitation
Timeline: Weeks 39-52 (7/1/2016 – 9/30/2017)

4b. Task: Conduct fMRI
Responsible personnel: Dr. Gadow, Dr. DeLorenzo, Coordinator

Milestone: Conduct fMRIs

Timeline: Weeks 39-52 (7/1/2016 – 9/30/2017)

4c. Task: Storing and processing Phase 2 fMRI data

Responsible personnel: Dr. DeLorenzo

Milestones and timeline: Storing and initial processing fMRI data Weeks 39-52 (7/1/2016-9/30/2017)

YEAR

Aim #5: Repeat everything in Aim #4, recruit 27 participants for Phase 1 and 21 participants for Phase 2

Timeline: Weeks 1-46 (10/1/2016 – 7/31/2018)

Aim #6: Analyze the data with regard to the stated hypotheses of the study

6. Task: Conduct data analyses

Responsible personnel: Dr. Yang, Dr. Gadow, Dr. DeLorenzo,

Milestones: Data analyses will be conducted using SPSS

Timeline: Weeks 46-52 (8/1/18 – 9/29/18)

Aim #7: Prepare abstracts, presentations, and manuscripts

7. Responsible personnel: Dr. Gadow, Dr. Parsey, Dr. DeLorenzo, Dr. Yang, Dr. Whitaker-Azmitia

Milestones: Submit proposals to present at national or international meetings and prepare for submission manuscripts to peer-reviewed journals

Timeline: Weeks 46-52 (8/1/18 – 9/29/18)

	Year 2				Year 3				Year 4			
Target Enrollment (per quarter)	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Phase 1			4	4	2	3	1	9	11*	8	8	
Phase 2			0	1	2	1	2	3	7**	7	7	
Target Enrollment (cumulative)												
Phase 1			4	8	10	13	14	23	34	42	50	
Phase 2			0	1	3	4	6	9	16	23	30	

* Three already scheduled or completed.

** Five already scheduled or completed.